<DOC>
	<DOCNO>NCT02665754</DOCNO>
	<brief_summary>The investigator perform double-blinded placebo-controlled randomized clinical trial evaluate efficacy safety allergen-specific intralymphatic immunotherapy ( ILIT ) allergens include Dermatophagoides farinae ( Df ) , Dermatophagoides pteronyssinus ( Dp ) , cat , dog sensitize provoke rhinitis-related symptom patient allergic rhinitis ( AR ) , use allergen extract allergen-specific immunotherapy ( Tyrosine S , Allergy Therapeutic , West Sussex , UK ) .</brief_summary>
	<brief_title>Intralymphatic Immunotherapy House Dust Mite , Dog , Cat Allergy Using Tyrosine S® Allergic Rhinitis</brief_title>
	<detailed_description>After informed consent , subject randomly assign ILIT group placebo group double-blind manner . In group , causal allergen placebo inject inguinal lymph node guidance ultrasonography three time 4-week interval . In ILIT group , initial dose allergen 1,000-fold diluted solution maximal concentration allergen extract subcutaneous immunotherapy ( Tyrosine S , Allergy Therapeutic , West Sussex , UK ) volume 0.1ml . If skin highly reactive skin prick test , initial dose 10-fold dilution maximal concentration diameter wheal less histamine . After first dose , allergen concentration escalate 3-fold second dose , 10-fold third dose ( mild ) local systemic hypersensitivity reaction . The allergen concentration change second third dose moderate local systemic reaction . The allergen concentration decrease 10 100-fold previous concentration injection hold severe local systemic reaction sufficient explanation discussion subject . The investigator evaluate allergic rhinitis symptom score 4 , 12 month initial treatment . Rhinoconjunctivitis Quality Life Questionnaire ( RQLQ ) Sino-Nasal Outcome Test ( SNOT-20 ) use . Visual analogue scale ( VAS ) symptoms include rhinorrhea , sneeze , nasal obstruction , postnasal drip , eye/nose/ear/palate itching , dyspnea , wheeze , chest discomfort well urticaria , angioedema , itch expose skin exposure causal allergen daily life also evaluate . Skin prick test ( SPT ) , intradermal test ( IDT ) , blood sample serum total immunoglobulin E ( IgE ) , allergen-specific IgE , allergen-specific immunoglobulin G4 ( IgG4 ) , nasal lavage Th1 , Th2 , Treg cytokine , nasal provocation test ( NPT ) Df and/or Dp allergen ( subject whose AR symptom provoke Df and/or Dp ) also perform 4 , 12 month initial treatment . In addition , investigator evaluate change subject ' recognition causal allergen , avoidance , AIT study . Using VAS , subject request score rate agreement `` Allergen provoke allergic symptom daily life '' , `` Allergen avoidance reduce allergic symptom '' , `` Allergen-specific Immunotherapy ( AIT ) reduce allergic symptom '' , `` I pay 50,000 Korean Won ( KRW ) /month allergen avoidance '' , `` I pay 100,000 KRW/month allergen avoidance '' , `` I pay 200,000 KRW/month allergen avoidance '' , `` I pay 150,000 KRW injection ILIT '' , `` I pay 300,000 KRW injection ILIT '' , `` I pay 600,000 KRW injection ILIT '' SPT/IDT , NPT , 4 month 1 year ILIT . Adverse event record grade accord Muller classification Ring Meissner classification .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>We enrol subject suffer AR , symptom provoke Dp , Df , dog , and/or cat allergen . Concretely , two inclusion criterion meet . 1 . Sensitization verify skin prick test level serum specific IgE measure ImmunoCAP® ( Thermo Fisher Scientific , Uppsala , Sweden ) . 2 . Subjects complain AR symptom exposure house dust , dog and/or cat daily life . 1 . Uncontrolled severe asthma accord Global Initiative Asthma ( GINA ) guideline include case force expiratory volume 1 ( FEV1 ) less 50 % predict value 2 . Significant cardiovascular , hepatic , renal , hematologic , oncologic , infectious disease 3 . Administration beta blocker , angiotensin convert enzyme inhibitor , tricyclic antidepressant , immunosuppressant include systemic glucocorticosteroid within last 2 week 4 . AR cause perennial seasonal allergen 5 . Prior history allergenspecific immunotherapy 6 . Rejection low compliance , 7 . Pregnancy lactation 8 . Vulnerable volunteer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Injection , intralymphatic</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Dermatophagoides farinae</keyword>
	<keyword>Dermatophagoides pteronyssinus</keyword>
	<keyword>Dogs</keyword>
	<keyword>Cats</keyword>
</DOC>